The limited activity of AZD1480 and ruxolitinib for the ALL PDXs tested was despite the models being highly represented by Ph-like and ETP subtypes harboring JAK1 or JAK2 mutations. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.